TEL AVIV, Israel, Nov. 23, 2016 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced it will provide a corporate overview in a “fireside chat” format at the 28th Annual Piper Jaffray Healthcare Conference. The conference is being held on November 29-30, 2016, at Lotte New York Palace Hotel in New York City.
|Event:||28th Annual Piper Jaffray Healthcare Conference|
|Date & Time:||Tuesday, November 29 @ 7:30am Eastern Time.|
|Location:||Lotte New York Palace Hotel in New York City, Ballroom Hubbard 1|
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is positioned to treat a wide range of solid tumors. It is conveniently administered as an IV infusion once every two months. It has been observed to be well-tolerated in >200 cancer patients and we have observed its efficacy signals in an “all comers” Phase 1 trial as well as in three tumor-specific Phase 2 studies. Ofranergene obadenovec is currently being studied in a Phase 3 pivotal trial for recurrent Glioblastoma, conducted under an FDA Special Protocol Assessment (SPA).
CONTACT: INVESTOR CONTACT: Michael Rice LifeSci Advisors, LLC (646) 597-6979